Four Decades for Justice
On January 31, 2023, Cravath partner David J. Kappos participated in the third annual Patent Trial & Appeal Board Masters 2023 conference, which was hosted by IPWatchdog from January 31 – February 1, 2023 in Ashburn, Virginia. Dave spoke on a panel entitled “Reforming the PTAB: What Can and Should be Done?” which discussed the feasibility of restructuring the U.S. Patent Trial and Appeal Board (“PTAB”), what changes could be accomplished through rulemaking and how the PTAB can improve fairness for both petitioners and patent owners.
Deals & Cases
January 25, 2023
On January 24, 2023, WiseTech Global, developer of leading logistics execution software CargoWise, announced its acquisition of Envase Technologies (“Envase”), a leading provider of transport management system software for intermodal trucking, drayage (container haulage) and landside logistics in North America, in a transaction valued at $230 million. Envase is being acquired from private investment firm and supply chain investor Firmament, and a small number of other sellers. Cravath is representing WiseTech Global in connection with the transaction.
Deals & Cases
November 07, 2022
On November 7, 2022, Viatris Inc. (“Viatris”), a global healthcare company, announced it intends to create an ophthalmology franchise by acquiring Oyster Point Pharma (“Oyster Point”) and Famy Life Sciences.
Deals & Cases
October 11, 2022
On October 11, 2022, Brookfield Renewable Partners (“Brookfield Renewable”), together with its institutional partners and Cameco Corporation (“Cameco”), announced they are forming a strategic partnership (“the consortium”) to acquire Westinghouse Electric Company (“Westinghouse”), one of the world’s largest nuclear services businesses, for a total enterprise value of $7.875 billion.
Deals & Cases
August 08, 2022
On August 8, 2022, Global Blood Therapeutics, Inc. (“GBT”), a biopharmaceutical company dedicated to the discovery, development and delivery of life‑changing treatments that provide hope to underserved patient communities, starting with sickle cell disease, and Pfizer Inc. (“Pfizer”) announced that the companies have entered into a definitive agreement under which Pfizer will acquire GBT. Under the terms of the transaction, Pfizer will acquire all the outstanding shares of GBT for $68.50 per share in cash, for a total enterprise value of approximately $5.4 billion, including debt and net of cash acquired. Cravath is representing GBT in connection with the transaction.
Celebrating 200 years of partnership. In 2019, we celebrated our bicentennial. Our history mirrors that of our nation. Integral to our story is our culture.
Attorney Advertising. ©2024 Cravath, Swaine & Moore LLP.